Literature DB >> 15670886

Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid.

Garry L Morefield1, Dongping Jiang, Ilia Z Romero-Mendez, Robert L Geahlen, Harm Hogenesch, Stanley L Hem.   

Abstract

The phosphate content of commercial ovalbumin was increased from 1.8 to 3.2 mol PO(4)/mol ovalbumin by conjugation of phosphoserine and reduced to 1.2 or 0.14 mol PO(4)/mol ovalbumin by treatment with potato acid phosphatase. The four ovalbumin samples were completely adsorbed by aluminum hydroxide adjuvant due to electrostatic attraction of the negatively charged ovalbumin and the positively charged aluminum hydroxide adjuvant as well as by ligand exchange of phosphate groups with surface hydroxyl groups. Elution from aluminum hydroxide adjuvant upon exposure to interstitial fluid was inversely related to the degree of phosphorylation of the ovalbumin. The ovalbumin sample containing 3.2 mol PO(4)/mol ovalbumin did not elute while the ovalbumin sample containing 0.14 mol PO(4)/mol ovalbumin eluted completely from aluminum hydroxide adjuvant during exposure to interstitial fluid for 30 min. Adsorption of the four ovalbumin samples by aluminum phosphate adjuvant was directly related to the degree of phosphorylation of ovalbumin. Adsorption was due to ligand exchange as an electrostatic repulsive force operated between the negatively charged ovalbumin samples and the negatively charged aluminum phosphate adjuvant. The potential for ligand exchange decreased as the phosphorylation of ovalbumin decreased. Elution upon exposure to interstitial fluid was inversely related to the degree of phosphorylation and was more extensive than observed for aluminum hydroxide adjuvant. Adsorption of ovalbumin by aluminum-containing adjuvants and elution upon exposure to interstitial fluid can be controlled by the degree of phosphorylation of both ovalbumin and the aluminum-containing adjuvant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670886     DOI: 10.1016/j.vaccine.2004.08.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  A rational, systematic approach for the development of vaccine formulations.

Authors:  Garry L Morefield
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

2.  The role of adjuvant in mediating antigen structure and stability.

Authors:  Latoya Jones Braun; Aimee M Eldridge; Jessica Cummiskey; Kelly K Arthur; Deborah S Wuttke
Journal:  J Pharm Sci       Date:  2011-12-28       Impact factor: 3.534

Review 3.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.

Authors:  Francesco Borriello; Valentina Poli; Ellen Shrock; Roberto Spreafico; Xin Liu; Novalia Pishesha; Claire Carpenet; Janet Chou; Marco Di Gioia; Marisa E McGrath; Carly A Dillen; Nora A Barrett; Lucrezia Lacanfora; Marcella E Franco; Laura Marongiu; Yoichiro Iwakura; Ferdinando Pucci; Michael D Kruppa; Zuchao Ma; Douglas W Lowman; Harry E Ensley; Etsuro Nanishi; Yoshine Saito; Timothy R O'Meara; Hyuk-Soo Seo; Sirano Dhe-Paganon; David J Dowling; Matthew Frieman; Stephen J Elledge; Ofer Levy; Darrell J Irvine; Hidde L Ploegh; David L Williams; Ivan Zanoni
Journal:  Cell       Date:  2022-02-10       Impact factor: 41.582

5.  Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies.

Authors:  Emi A Lutz; Yash Agarwal; Noor Momin; Sarah C Cowles; Joseph R Palmeri; Ellen Duong; Vladlena Hornet; Allison Sheen; Brianna M Lax; Adrienne M Rothschilds; Darrell J Irvine; Stefani Spranger; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

6.  Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity.

Authors:  Yash Agarwal; Lauren E Milling; Jason Y H Chang; Luciano Santollani; Allison Sheen; Emi A Lutz; Anthony Tabet; Jordan Stinson; Kaiyuan Ni; Kristen A Rodrigues; Tyson J Moyer; Mariane B Melo; Darrell J Irvine; K Dane Wittrup
Journal:  Nat Biomed Eng       Date:  2022-01-10       Impact factor: 29.234

Review 7.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

8.  Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution.

Authors:  Christina Vessely; Tia Estey; Theodore W Randolph; Ian Henderson; Julianne Cooper; Rajiv Nayar; Latoya Jones Braun; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

9.  Active self-healing encapsulation of vaccine antigens in PLGA microspheres.

Authors:  Kashappa-Goud H Desai; Steven P Schwendeman
Journal:  J Control Release       Date:  2012-10-24       Impact factor: 9.776

10.  Aluminum hydroxide influences not only the extent but also the fine specificity and functional activity of antibody responses to tick-borne encephalitis virus in mice.

Authors:  Juergen Zlatkovic; Georgios Tsouchnikas; Johanna Jarmer; Christian Koessl; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.